Efficacy and safety of modified BLd therapy for Japanese patients with transplant-ineligible multiple myeloma

Murakami, Satona; Ri, Masaki; Ito, Masato; Nakamura, Nobuhiko; Kasahara, Senji; Kitagawa, Junichi; Inagaki, Yuichiro; Kuroda, Junya; Yoshimitsu, Makoto; Okamoto, Akinao; Fukuhara, Noriko; Taji, Hirofumi; Iida, Hiroatsu; Nagai, Hirokazu; Hanamura, Ichiro; Tsujimura, Hideki; Okura, Miyuki; Kurata, Mio; Kuwatsuka, Yachiyo; Atsuta, Yoshiko; Iida, Shinsuke

doi:10.1007/s12185-022-03379-9

Cited by 1 publication

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on the studies with available PFS data, three studies were included in the daratumumab-based regimen group ( 15 , 16 , 19 ) and four in the RVD/RVD-lite group ( 8 , 12 , 20 , 21 ). Survival curves for the PFS of the two groups are shown in Figures 5A , B .…”

Section: Resultsmentioning

confidence: 99%

“…For the meta-analysis of OS, two studies with available data were included in the daratumumab-based regimen group ( 16 , 19 ) and four in the RVD/RVD-lite group ( 8 , 12 , 20 , 21 ). The median OS of both groups was not reached, and there were no significant differences in OS between the two groups (HR 1.03, 95%CI, 0.86-1.23) ( Figures 5C, D ).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review

Tang,

Zhang,

Zheng

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

BackgroundSince no randomized controlled trials have directly compared the efficacy and safety of immunotherapy with daratumumab versus lenalidomide/bortezomib/dexamethasone (RVD) in the frontline treatment of transplant-ineligible newly diagnosed multiple myeloma (TIE-NDMM), this study systematically reviewed the clinical studies regarding immunotherapy with daratumumab and RVD regimen in the treatment of TIE-NDMM to explore the optimization direction of the best first-line therapy.MethodsThe Cochrane Library, PubMed, Embase, and Web of Science databases were searched to collect studies on regimens containing daratumumab or RVD/RVD-lite for TIE-NDMM. Pooled and meta-analysis was then performed to compare the overall response rate (ORR), stringent complete remission (sCR) and CR rate, progression-free survival (PFS), overall survival (OS) and treatment-related discontinuation rate between daratumumab-containing immunotherapy regimen and RVD/RVD-lite regimen by using R 4.3.1 software.ResultsNine prospective clinical trials were included, including 1795 TIE-NDMM or NDMM without intent for immediate ASCT. Among them, 938 patients were treated with daratumumab-based immunotherapy and 857 with RVD/RVD-lite regimens. Meta-analysis results showed that The daratumumab-based regimen showed a significantly higher CR/sCR rate than RVD/RVD-lite for TIE-NDMM (47% vs. 24%, P<0.01). The median PFS of the daratumumab-based and RVD/RVD-lite groups were 52.6 months and 35.1 months respectively (HR 0.77, 95%CI, 0.66-0.90). The median OS of both groups was not reached, and there were no significant differences in OS between the two groups (HR 1.03, 95%CI, 0.86-1.23). The therapy discontinuation rate led by adverse events was significantly higher in the RVD/RVD-lite group than in the daratumumab-based regimen group for the TIE-NDMM (16% vs. 7%, P=0.03).ConclusionThis meta-analysis suggests that daratumumab-containing immunotherapy is superior to RVD in the depth of treatment efficacy, progression-free survival, and lower treatment-related discontinuation rates. Limited by the lack of head-to-head clinical trials, this conclusion needs to be verified by concurrent cohort studies.

show abstract